CN110167550A - 西克里维罗甲磺酸盐的固体形式及其制备方法 - Google Patents

西克里维罗甲磺酸盐的固体形式及其制备方法 Download PDF

Info

Publication number
CN110167550A
CN110167550A CN201780061529.6A CN201780061529A CN110167550A CN 110167550 A CN110167550 A CN 110167550A CN 201780061529 A CN201780061529 A CN 201780061529A CN 110167550 A CN110167550 A CN 110167550A
Authority
CN
China
Prior art keywords
msoh
compound
crystalline form
acetonitrile
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780061529.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·菲亚芳萨
M·I·库珀
E·K·夏普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tobira Therapeutics Inc
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of CN110167550A publication Critical patent/CN110167550A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780061529.6A 2016-08-31 2017-08-30 西克里维罗甲磺酸盐的固体形式及其制备方法 Pending CN110167550A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
US62/382,153 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
CN110167550A true CN110167550A (zh) 2019-08-23

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780061529.6A Pending CN110167550A (zh) 2016-08-31 2017-08-30 西克里维罗甲磺酸盐的固体形式及其制备方法

Country Status (13)

Country Link
US (1) US10301287B2 (enExample)
EP (1) EP3506896A4 (enExample)
JP (2) JP2019526628A (enExample)
KR (1) KR20190057066A (enExample)
CN (1) CN110167550A (enExample)
AU (1) AU2017321594A1 (enExample)
BR (1) BR112019003987A2 (enExample)
CA (1) CA3034606A1 (enExample)
MX (1) MX2019002057A (enExample)
RU (1) RU2019109019A (enExample)
SG (1) SG11201901438VA (enExample)
TW (1) TW201823235A (enExample)
WO (1) WO2018045043A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245589A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245534A1 (en) * 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
EP4159730A4 (en) 2020-05-22 2024-05-01 Medshine Discovery Inc. PYRIDINE DERIVATIVE AND APPLICATION THEREOF
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
EP1104416A2 (en) 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2384145A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
EP1728504B1 (en) 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsion stabilizer
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2818308A1 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
CA2941411A1 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
WO2015187663A1 (en) * 2014-06-02 2015-12-10 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
SG11201704837VA (en) 2014-12-23 2017-07-28 Tobira Therapeutics Inc Process of making cenicriviroc and related analogs

Also Published As

Publication number Publication date
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
RU2019109019A3 (enExample) 2021-08-23
WO2018045043A1 (en) 2018-03-08
RU2019109019A (ru) 2020-10-01
US20180057481A1 (en) 2018-03-01
SG11201901438VA (en) 2019-03-28
TW201823235A (zh) 2018-07-01
KR20190057066A (ko) 2019-05-27
AU2017321594A1 (en) 2019-04-18
US10301287B2 (en) 2019-05-28
BR112019003987A2 (pt) 2019-05-28
EP3506896A1 (en) 2019-07-10
MX2019002057A (es) 2019-11-18
EP3506896A4 (en) 2020-08-26
CA3034606A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
JP6081763B2 (ja) ダサチニブ多形体およびその調製プロセス
JP7199739B2 (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
EP3344607B1 (en) Solid state forms of selexipag
CN104220431A (zh) 卡巴他赛的固态形式及其制备方法
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
EP3565819B1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2018022704A1 (en) Crystalline form vi of selexipag
WO2018233591A1 (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
US9212172B2 (en) Preparation of crystalline bazedoxifene and its salts
TW202434600A (zh) 磺醯胺衍生物結晶形式及其製備方法
US11434204B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
WO2023143576A1 (zh) 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式
US20160122274A1 (en) Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore
TW202140493A (zh) 2-吲哚啉螺環酮類化合物或其鹽、溶劑錯合物之非晶形式或結晶形式
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
RU2792728C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ 3-[5-АМИНО-4-(3-ЦИАНОБЕНЗОИЛ)ПИРАЗОЛ-1-ил]-N-ЦИКЛОПРОПИЛ-4-МЕТИЛБЕНЗАМИДА
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途
EP4608832A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
HK40001929A (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
HK40001929B (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190823

WD01 Invention patent application deemed withdrawn after publication